Evotec's Strong Q3 2026 Results: A Path to Growth by 2030

Evotec SE, highlighted significant achievements in its third quarter of 2026, focusing on strategic targets for 2030. Group revenue for Q3 stood at €164.9 million, while the nine-month total reached €465.0 million. Despite presenting a challenging adjusted EBITDA of -€1.6 million for Q3, Evotec reaffirms its 2026 guidance with expected revenue between €570 to €610 million. The company anticipates a Group revenue ambition close to €1 billion by 2030.

Noteworthy advancements include the selection of Just – Evotec Biologics by Vertex Pharmaceuticals for manufacturing povetacicept and the initiation of a Phase 1 clinical trial under collaboration with the U.S. Department of War. Recent partnerships, like those with Plectonic and Odyssey Therapeutics, emphasize innovation through advanced technology platforms.

Evotec's Horizon transformation progressed ahead of schedule, achieving over 20% of the targeted €75 million annual savings by September. Leadership sees a promising future, as strategic partnerships evolve to bolster commercial growth.